Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Holding VKTX?
Track your performance easily
VKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.47 - $99.41
Previous CloseN/A
Volume685.03K
Average Volume (3M)3.53M
Market Cap
$3.63B
Enterprise Value$6.09B
Total Cash (Recent Filing)$13.15M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.14
Next Earnings
Feb 05, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding111,436,386
10 Day Avg. Volume3,354,104
30 Day Avg. Volume3,526,094
Standard Deviation0.38
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-44.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-56.74
Forecast
1Y Price Target
$112.18Price Target Upside244.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Viking Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentViking Therapeutics announced the initiation of its Phase 2 clinical trial for oral VK2735, which is a key step in the weight loss drug development journey.
Competitive LandscapeViking gains traction as Novo falls short on weight loss expectations, highlighting opportunities for smaller biotechs like Viking.
Intellectual Property And Market ExclusivityViking Therapeutics has robust intellectual property protection for VK2735, potentially extending exclusivity beyond 2040 with additional patent applications pending.
Bears Say
Competitive LandscapeShares of Viking are down following Merck’s announcement, reflecting increased investor scrutiny on the competitive landscape in the GLP-1 field.
Efficacy And Safety ConcernsLack of transparency around efficacy and safety of MariTide gives pause about the future of the obesity treatment landscape.
Financial PerformanceTotal operating expenses in 3Q24 were slightly higher than expected due to G&A expenses.
---
Ownership Overview
2.79% Insiders
27.49% Mutual Funds
0.32% Other Institutional Investors
55.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $20.47 and its highest was $99.41 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.63B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Feb 05, 2025 which is in 18 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Oct 23, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.023.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 111,436,386 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went up 21.245%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Among the largest hedge funds holding Viking Therapeutics’s share is Perceptive Advisors LLC. It holds Viking Therapeutics’s shares valued at 108M.
---
Viking Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.18 (244.53% Upside)
$112.18 (244.53% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 342.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.15%
12-Months-Change
Fundamentals
Return on Equity
-10.88%
Trailing 12-Months
Asset Growth
145.09%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
VKTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Viking Therapeutics demonstrated significant progress with their clinical programs and strong financial positioning, although increased expenses and pending regulatory approvals present challenges. The overall sentiment is balanced by these factors.Read More>---
VKTX Stock 12 Month Forecast
Average Price Target
$112.18
▲(244.53% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Akero Therapeutics
―
Royalty Pharma
―
Axsome Therapeutics
―
Regulus
―
Best Analysts Covering VKTX
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+182.33%
reiterated a buy rating 3 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +182.33% per trade.
---